NVLNF has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NVLNF has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Novelion Therapeutics's Total Assets for the quarter that ended in Mar. 2019 was $342.1 Mil.
Total Assets is connected with ROA %. Novelion Therapeutics's annualized ROA % for the quarter that ended in Mar. 2019 was -37.26%. Total Assets is also linked to Revenue through Asset Turnover. Novelion Therapeutics's Asset Turnover for the quarter that ended in Mar. 2019 was 0.09.
The historical data trend for Novelion Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novelion Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | |||||||||||
Total Assets | Get a 7-Day Free Trial | 160.37 | 145.17 | 480.78 | 369.32 | 341.72 |
Novelion Therapeutics Quarterly Data | ||||||||||||||||||||
Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | |
Total Assets | Get a 7-Day Free Trial | 358.47 | 340.33 | 324.99 | 341.72 | 342.12 |
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Novelion Therapeutics's Total Assets for the fiscal year that ended in Dec. 2018 is calculated as
Total Assets | = | Total Equity (A: Dec. 2018 ) | + | Total Liabilities (A: Dec. 2018 ) |
= | -88.86 | + | 430.575 | |
= | 341.7 |
Novelion Therapeutics's Total Assets for the quarter that ended in Mar. 2019 is calculated as
Total Assets | = | Total Equity (Q: Mar. 2019 ) | + | Total Liabilities (Q: Mar. 2019 ) |
= | -118.949 | + | 461.069 | |
= | 342.1 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novelion Therapeutics (OTCPK:NVLNF) Total Assets Explanation
Total Assets is connected with ROA %.
Novelion Therapeutics's annualized ROA % for the quarter that ended in Mar. 2019 is
ROA % | = | Net Income (Q: Mar. 2019 ) | / | ( (Total Assets (Q: Dec. 2018 ) | + | Total Assets (Q: Mar. 2019 )) | / count ) |
= | -127.388 | / | ( (341.715 | + | 342.12) | / 2 ) | |
= | -127.388 | / | 341.9175 | ||||
= | -37.26 % |
Note: The Net Income data used here is four times the quarterly (Mar. 2019) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Novelion Therapeutics's Asset Turnover for the quarter that ended in Mar. 2019 is
Asset Turnover | ||||||
= | Revenue (Q: Mar. 2019 ) | / | ( (Total Assets (Q: Dec. 2018 ) | + | Total Assets (Q: Mar. 2019 )) | / count ) |
= | 32.2 | / | ( (341.715 | + | 342.12) | / 2 ) |
= | 32.2 | / | 341.9175 | |||
= | 0.09 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Thank you for viewing the detailed overview of Novelion Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Kevin Kotler | 10 percent owner | C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Broadfin Capital, Llc | 10 percent owner | 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Broadfin Healthcare Master Fund Ltd | 10 percent owner | C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108 |
Stonepine Capital, L.p. | 10 percent owner | 919 NW BOND STREET, SUITE 204, BEND OR 97703 |
Michael Dennis Price | officer: Chief Financial Officer | |
Benjamin Harshbarger | officer: See Remarks | ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142 |
Mark Dipaolo | director | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
John J Orloff | director | C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015 |
Stephen L Sabba | director | DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791 |
Mark Corrigan | director | |
Suzanne Louise Bruhn | director | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746 |
John C Thomas | director | 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615 |
Murray Stewart | officer: Executive Vice President, R&D | C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3 |
Jason Aryeh | director | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Mary T Szela | director, officer: Chief Executive Officer | 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121 |
From GuruFocus
By PRNewswire PRNewswire • 11-12-2018
By Marketwired Marketwired • 06-24-2019
By Marketwired Marketwired • 02-06-2019
By Marketwired Marketwired • 01-03-2020
By Marketwired Marketwired • 02-28-2019
By Marketwired Marketwired • 08-22-2019
By Marketwired Marketwired • 11-21-2018
By Marketwired Marketwired • 11-08-2018
By Marketwired Marketwired • 10-08-2019
By Marketwired Marketwired • 09-12-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.